Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Takes Position in Haemonetics Co. (NYSE:HAE)

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA purchased a new stake in Haemonetics Co. (NYSE:HAE) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 461 shares of the medical instruments supplier’s stock, valued at approximately $58,000.

Other large investors have also modified their holdings of the company. Retirement Systems of Alabama grew its position in shares of Haemonetics by 0.3% in the second quarter. Retirement Systems of Alabama now owns 66,603 shares of the medical instruments supplier’s stock valued at $8,015,000 after purchasing an additional 205 shares during the last quarter. Arizona State Retirement System grew its position in Haemonetics by 1.5% during the second quarter. Arizona State Retirement System now owns 37,164 shares of the medical instruments supplier’s stock worth $4,472,000 after buying an additional 538 shares in the last quarter. Emerald Advisers LLC grew its position in Haemonetics by 15.6% during the second quarter. Emerald Advisers LLC now owns 181,170 shares of the medical instruments supplier’s stock worth $21,802,000 after buying an additional 24,410 shares in the last quarter. Eagle Asset Management Inc. lifted its stake in Haemonetics by 2.9% during the third quarter. Eagle Asset Management Inc. now owns 595,932 shares of the medical instruments supplier’s stock worth $75,170,000 after purchasing an additional 16,962 shares during the period. Finally, Oakbrook Investments LLC bought a new position in Haemonetics during the second quarter worth about $439,000. 99.96% of the stock is currently owned by institutional investors.

In other news, SVP Jacqueline Scanlan sold 1,531 shares of Haemonetics stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $127.44, for a total value of $195,110.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Christopher Simon sold 50,869 shares of Haemonetics stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $137.43, for a total transaction of $6,990,926.67. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 103,735 shares of company stock valued at $13,462,081. Corporate insiders own 1.32% of the company’s stock.

HAE traded down $0.39 during midday trading on Wednesday, reaching $120.29. 6,616 shares of the company’s stock were exchanged, compared to its average volume of 429,012. The firm has a market capitalization of $6.04 billion, a price-to-earnings ratio of 50.35, a price-to-earnings-growth ratio of 2.78 and a beta of 0.77. The company has a quick ratio of 1.35, a current ratio of 2.37 and a debt-to-equity ratio of 0.54. Haemonetics Co. has a one year low of $80.24 and a one year high of $140.36. The business has a 50-day simple moving average of $124.49 and a two-hundred day simple moving average of $118.25.

A number of research analysts have commented on the stock. Jefferies Financial Group raised their price target on shares of Haemonetics from $125.00 to $140.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Raymond James raised their price target on shares of Haemonetics from $110.00 to $150.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 7th. JMP Securities raised their price target on shares of Haemonetics to $145.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 7th. Barrington Research restated a “buy” rating and set a $141.00 price target on shares of Haemonetics in a research note on Monday, November 4th. Finally, ValuEngine cut shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Monday. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company has an average rating of “Buy” and an average price target of $144.80.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Further Reading: What is Depreciation?

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.